LEADER 04521nam 2201021z- 450 001 9910580213903321 005 20220706 035 $a(CKB)5690000000011949 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/87533 035 $a(oapen)doab87533 035 $a(EXLCZ)995690000000011949 100 $a20202207d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aNeurotransmitter-Related Molecular Modeling Studies 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (188 p.) 311 08$a3-0365-4277-9 311 08$a3-0365-4278-7 330 $aThis book focuses of the neurotransmission phenomenon. By definition, neurotransmitters are chemicals that enable communication, i.e., the flow of nerve impulses between nerve cells or between nerve cells and muscles and glands. Recently, one can distinguish excitatory and inhibitory mediators, both of which are endo-exogenous compounds that control the function of the whole organism. From a chemical point of view, neurotransmitters belong to many different structural groups, such as amino acids (such as glycine), peptides (such as substance P, somatostatin), monoamines (such as noradrenaline or dopamine), purine derivatives (such as adenosine), gases (such as nitrogen, NO, carbon monoxide CO), and acetylcholine. From a medical point of view, disturbances in the concentration of neurotransmitters in the body result in the occurrence of mental disorders and diseases (such as depression, schizophrenia, Parkinson's disease) and contribute to the occurrence of dementia (including Alzheimer's disease), among other diseases. However, the problem is much wider. These disorders can lead to a number of cardiovascular diseases and can lead to the development of vascular diseases of the brain as well as in many other organs. Therefore, pharmacological intervention is a therapy that tries to interfere with regulatory processes year after year. Such treatments improve survival, reduce the frequency of readmission, and improve patients' quality of life. 606 $aChemistry$2bicssc 606 $aResearch & information: general$2bicssc 610 $a3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors 610 $a5-HT receptors 610 $aacetylcholine 610 $aadverse drug reaction 610 $aandrogenetic alopecia 610 $aantibiotics 610 $aatheroprotection 610 $aBDNF 610 $acardiac voltage-gated ion channels 610 $achronic heart failure (CHF) 610 $acognitive impairment 610 $adementia 610 $adepression 610 $adopamine 610 $adysautonomia 610 $aECG study 610 $agastrointestinal tract 610 $agenetic polymorphisms 610 $aglutamate 610 $aguanylate cyclase (GC) 610 $ahalogenated pyrazolines 610 $ainflammation 610 $akinetics 610 $alevodopa 610 $amixed dyslipidemia 610 $amolecular dynamics 610 $amolecular modeling 610 $amonoamine oxidase inhibitors 610 $amouse 610 $amTOR 610 $aneurodegenerative diseases 610 $aneuroprotection 610 $aneurotoxicity 610 $aneurotransmission 610 $aneurotransmitters 610 $aorthostatic hypotension 610 $aoxidative stress 610 $apulmonary arterial hypertension (PAH) 610 $arenin-angiotensin system 610 $areserpine-induced fibromyalgia model 610 $areversibility 610 $arisk factors 610 $aropinirole 610 $aserotonin 610 $aserotonin and dopamine in fibromyalgia 610 $aSGLT2i 610 $asodium-glucose cotransporter 2 inhibitors 610 $astatins 610 $astroke 610 $atiagabine 610 $atype 2 diabetes mellitus 610 $avortioxetine 610 $awhite matter hyperintensities 615 7$aChemistry 615 7$aResearch & information: general 700 $aNowaczyk$b Alicja$4edt$01332311 702 $aGrze?k$b Grzegorz$4edt 702 $aNowaczyk$b Alicja$4oth 702 $aGrze?k$b Grzegorz$4oth 906 $aBOOK 912 $a9910580213903321 996 $aNeurotransmitter-Related Molecular Modeling Studies$93040814 997 $aUNINA